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ABSTRACT: Ligase IV syndrome is a rare differential diag-
nosis for Nijmegen breakage syndrome owing to a shared
predisposition to lympho-reticular malignancies, signifi-
cant microcephaly, and radiation hypersensitivity. Only
16 cases with mutations in LIG4 have been described to
date with phenotypes varying from malignancy in devel-
opmentally normal individuals, to severe combined im-
munodeficiency and early mortality. Here, we report the
identification of biallelic truncating LIG4 mutations in 11
patients with microcephalic primordial dwarfism present-
ing with restricted prenatal growth and extreme postna-
tal global growth failure (average OFC −10.1 s.d., height
−5.1 s.d.). Subsequently, most patients developed throm-
bocytopenia and leucopenia later in childhood and many
were found to have previously unrecognized immunod-
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eficiency following molecular diagnosis. None have yet
developed malignancy, though all patients tested had cel-
lular radiosensitivity. A genotype–phenotype correlation
was also noted with position of truncatingmutations corre-
sponding to disease severity. This work extends the pheno-
typic spectrum associated with LIG4mutations, establish-
ing that extreme growth retardation with microcephaly is
a common presentation of bilallelic truncating mutations.
Such growth failure is therefore sufficient to consider a
diagnosis of LIG4 deficiency and early recognition of such
cases is important as bone marrow failure, immunodefi-
ciency, and sometimes malignancy are long term sequelae
of this disorder.
Hum Mutat 35:76–85, 2014. Published 2013 Wiley Periodicals,
Inc.∗
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Introduction
Ligase IV syndrome (MIM#606593) is a disorder ofDNAdamage
repair, with cellular hypersensitivity to ionizing radiation, caused by
mutations in LIG4 (MIM #601837). To date, only 16 cases from 12
C© 2013 The Authors. ∗Human Mutation published by Wiley Periodicals, Inc.
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families have been described with a high degree of clinical het-
erogeneity. The first case to be reported was a “developmentally
normal” 14-year-old boy (with presumably normal growth) who
exhibited severe radiosensitivity during treatment for leukemia
[Riballo et al., 1999;Riballo et al., 2001].LIG4mutationswere subse-
quently reported in individuals withmicrocephaly, mild immunod-
eficiency, developmental delay, and pancytopenia [O’Driscoll et al.,
2001, 2004; Unal et al., 2009]. Ligase IV syndrome was therefore
recognized as a rare differential for Nijmegen breakage syndrome
(NBS) [Ben-Omran et al., 2005]. LikeNBS, wheremild short stature
is present in many cases [Weemaes, 2000], reduced height has also
been reported in some LIG4 cases [Buck et al., 2006b; Gruhn et al.,
2007; O’Driscoll et al., 2001; Toita et al., 2007; Unal et al., 2009;
Yue et al., 2013]. However unlike NBS, LIG4 mutations are also
described in individuals with severe combined immunodeficiency
(SCID) [Buck et al., 2006b; Enders et al., 2006; Grunebaum et al.,
2008; van der Burg et al., 2006].
LIG4 is essential for the nonhomologous end joining (NHEJ)
of DNA following double strand breaks [Grawunder et al., 1998a].
It complexes with XRCC4, which localizes LIG4 to the site of DNA
damage [Berg et al., 2011], where LIG4 acts in the final step ofNHEJ,
ligating the DNA strands together [Helleday et al., 2007]. Patient
cells with LIG4mutations have increased sensitivity to DNA double
strand breaks induced by ionizing radiation [O’Driscoll et al., 2001].
NHEJ is also required to rejoin the variable, diversity, and joining
gene segments at the T- and B-cell receptor loci (V(D)J recombi-
nation) [Tonegawa, 1983] as well as in class switch recombination
[Casellas et al., 1998; Pan-Hammarstrom et al., 2005]. These pro-
cesses are essential for adaptive immunity and are defective in LIG4
patients, resulting in SCID in some cases [Buck et al., 2006b; Pan-
Hammarstrom et al., 2005; van der Burg et al., 2006]. SCID is also a
feature of infants with mutations in three other components of the
NHEJ machinery; DCLRE1C, encoding Artemis [Moshous et al.,
2001], PRKDC, encoding the catalytic subunit of DNA-PK (DNA-
dependent protein kinase) [van der Burg et al., 2009], and NHEJ1,
encoding Cernunnos-XLF [Buck et al., 2006a].
Microcephalic primordial dwarfism(MPD) is definedby thepres-
ence of both prenatal and postnatal growth restriction resulting in
extreme reduction in both head circumference (OFC) and height
(more than 4 s.d. below the population mean) [Klingseisen and
Jackson, 2011]. MPD represents a group of rare Mendelian disor-
ders, with causative genes affecting cell cycle progression through
roles in centriole duplication (CEP152, CENPJ) [Al-Dosari et al.,
2010; Kalay et al., 2011], DNA replication (ORC1, ORC4, ORC6,
CDC6, CDT1,MCM4) [Bicknell et al., 2011a; Bicknell et al., 2011b;
Gineau et al., 2012; Hughes et al., 2012], ATR-dependent DNA
damage response signaling and repair (PCNT,ATR,ATRIP, RBBP8)
[O’Driscoll et al., 2003; Ogi et al., 2012; Qvist et al., 2011; Rauch
et al., 2008] andmitotic spindle organization (PCNT) [Zimmerman
et al., 2004].
Here, we report the identification of biallelic truncating LIG4
mutations in a group of patients presenting with MPD. We provide
detailed molecular and phenotypic characterization of our patients,
and establish that the phenotype in Ligase IV syndrome can be
one of severe growth retardation with or without accompanying
pancytopenia or SCID.
Materials and Methods
Patients
Patients were recruited to research studies at the MRC Human
Genetics Unit in Edinburgh, UK, the Institute of Human Genetics
at the University of Cologne, Germany and the Nemours Founda-
tion, Delaware by their local clinician. The research studies were
approved by the multicenter research ethics committee for Scotland
(04:MRE00/19), Cologne hospitals ethics board, and the Nemours
Office of Human Subject Protection (NOHSP) & Institutional Re-
view Board respectively. Informed consent was obtained from all
families. Medical history, anthropometric data, examination find-
ings, and clinical laboratory results were obtained by questionnaire
fromthe referringphysician.All patients selected into the studyhada
clinical diagnosis ofMPDbased on head (occipital–frontal) circum-
ference (OFC) and height being more than 4 standard deviations
(s.d.) below the population mean at the time of study recruitment
(subsequent height measurements in three cases were between –3
and –4 s.d (F4, F6, and F9)). Standard deviations for height, weight,
and OFC normalized for age and sex were calculated using Cole’s
LMS method using UK 1990 cohort data [Freeman et al., 1995].
Age at examination was corrected for prematurity where birth was
before 37 weeks gestation and age <2 years. Age was then rounded
to the nearest month before s.d. calculation.
Exome Sequencing and Variant Validation
Genomic DNA was extracted from peripheral blood by standard
methods or saliva samples using Oragene collection kits according
to manufacturer’s instructions. Whole exome capture and sequenc-
ing was performed at the Wellcome Trust Sanger Institute (WTSI),
UK, and at the University of Cologne, Germany [Asharani et al.,
2012]. DNA was sheared to 150 bp lengths by sonification (Covaris,
Woburn, MA) before whole exome capture and amplification us-
ing the SureSelect Human All Exon 50Mb kit (Agilent, Santa Clara,
CA). Fragments were sequenced using Illumina Hiseq platform.
75 bp paired end sequence reads were aligned to the Genome Ref-
erence Consortium human build 37 reference sequence using BWA
[Li and Durbin, 2009]. Single nucleotide variants were called using
GenomeAnalysisTK (www.broadinstitute.org/gatk/) and SAMtools
(www.samtools.sourceforge.net/), whereas Indels were called using
Dindel (www.sanger.ac.uk/resources/software/dindel/) and SAM-
tools. Variants were then annotated with functional consequence
using Ensembl Variant Effect Predictor [McLaren et al., 2010].
Allele frequency from 1000genomes [Clarke et al., 2012] and db-
SNP (www.ncbi.nlm.nih.gov/projects/SNP/) databases were used
for filtering of population variants. Datasets were analyzed under a
model of autosomal recessive inheritance. Variants with the most
deleterious effect on protein function (stop gained and frameshift)
were prioritized for follow up and confirmed by bidirectional cap-
illary dye-terminator sequencing as previously described [Bicknell
et al., 2011b].
Capillary sequencing was performed in the MRC Human Ge-
netics Unit, Edinburgh, UK, (patient F10-sequencing performed
in the Erasmus Medical Centre, Rotterdam, The Netherlands).
Variants were annotated using the reference sequence, GenBank:
NM 002312.3, on the basis of coding sequence with nucleotides
numbered from first base of initiation codon (ATG). All variants re-
ported in this article have been submitted to the LeidenOpen Varia-
tion Database (LOVD v.3.0, http://www.lovd.nl/3.0/home). Primer
sequences and PCR conditions for LIG4 are available on request.
Haplotype Analysis
Twenty highly polymorphic SNPs (heterozygosity>0.46) present
within a 2 Mb region flanking LIG4 were genotyped by capillary
sequencing.
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Table 1. LIG4 Mutations Identified in 10 Families (F1–10) with a Clinical Diagnosis of Microcephalic Primordial Dwarfism
Patient Nucleotide change Protein change
Country of
Origin Mother Father
Size of
p.Arg814∗
associated
haplotype
F1.1 c.[2440C>T] p.(Arg814∗) Canada p.(Arg814∗) p.(Lys424Argfs∗20) 1.49 Mb
+[1271 1275delAAAGA] p.(Lys424Argfs∗20)
F1.2 c.[2440C>T] p.(Arg814∗) Canada p.(Arg814∗) p.(Lys424Argfs∗20) 1.49 Mb
+[1271 1275delAAAGA] p.(Lys424Argfs∗20)
F2 c.[2440C>T] p.(Arg814∗) USA p.(Arg814∗) N/A 1.29 Mb
+[2094C>G] p.(Tyr698∗)
F3 c.[2440C>T] p.(Arg814∗) Australia p.(Arg814∗) p.(Ala797Aspfs∗3) None
+[2386 2389dupATTG] p.(Ala797Aspfs∗3)
F4 c.[2440C>T] p.(Arg814∗) UK p.(Lys424Argfs∗20) p.(Arg814∗) >2 Mb
+[1271 1275delAAAGA] p.(Lys424Argfs∗20)
F5 c.[2440C>T] p.(Arg814∗) USA p.(Arg814∗) p.(Lys424Argfs∗20) None
+[1271 1275delAAAGA] p.(Lys424Argfs∗20)
F6 c.[2440C>T] p.(Arg814∗) Germany p.(Arg814∗) p.(Lys424Argfs∗20) 1.19 Mb
+[1271 1275delAAAGA] p.(Lys424Argfs∗20)
F7 c.[2440C>T] p.(Arg814∗) USA N/A N/A N/A
+[1512 1513delTC] p.(Arg505Cysfs∗12)
F8 c.[2440C>T] p.(Arg814∗) UK N/A N/A >2 Mb
+[1246 1250dupGATGC] p.(Leu418Metfs∗3)
F9 c.[2440C>T] p.(Arg814∗) Turkey p.(Arg814∗) p.(Lys424Argfs∗20) None
+[1271 1275delAAAGA] p.(Lys424Argfs∗20)
F10 c.[613delT] p.(Ser205Leufs∗29) The Netherlands p.(Ser205Leufs∗29) p.(Lys635Argfs∗10) N/A
+[1904delA] p.(Lys635Argfs∗10)
F1.1 and F1.2 represent individual affected siblings. All mutations are predicted to cause premature truncation of the protein. Nucleotides numbered from first base of initiation
codon (ATG) in coding DNA sequence [GenBank: NM_002312.3]. N/A, not available.
Statistical Analysis
Percentage of normal hematological parameters was calculated by
taking the midpoint of the reference range provided by the patient’s
diagnostic hematology lab. Significance testing was performed on
quantitative data using unpaired and paired Student’s t-tests.
Colony Survival Assays
Lymphoblastoid cell lines (LCLs) were derived from peripheral
blood lymphocytes and transformedwith Epstein–Barr virus. Ioniz-
ing radiation clonogenic survival assays were performed using a pre-
viously validated method [Sun et al., 2002] in which dose–response
curves were initially generated to identify suitable doses of ioniz-
ing radiation needed to discriminate wild-type and radiosensitive
LCLs.
Results
Compound Heterozygous Truncating Mutations in LIG4
Cause Extreme Growth Failure
Exome sequencing performed in 55 patients selected from a co-
hort of 138 patients withMPD, identified LIG4mutations in five pa-
tients. Initially, with variant filtering performed removing all dbSNP
variants with assigned “rs” accession numbers, only one heterozy-
gous truncating mutation in LIG4 was apparent in each patient.
However, refiltering the dataset to include all variants with an allele
frequency of less than 0.01 in the 1000 genomes dataset [Clarke
et al., 2012], identified a second mutation, c.2440C>T (p.Arg814∗,
rs104894419, allele frequency 0.003), in all five cases.
Mutations were subsequently identified in six additional individ-
uals, by capillary sequencing LIG4 in the remaining patients from
the sameMPDcohortwhohadnot been exome sequenced.A further
patient was identified with a single heterozygous truncating muta-
tion, c.128delT (p.Leu43∗), however, a second pathogenic variant
was not identified. Therefore, in total, 11 patients from 10 families
were identifiedwith biallelic truncatingmutations in LIG4 from 138
MPD patients (Table 1).
Biallelic LIG4 mutations were therefore present in 9% of MPD
cases screened without a previous molecular diagnosis and rep-
resented 2.4% of our total MPD families. Forty-three cases with
primary microcephaly and 56 with microcephaly and milder short
stature (height between –2 and –4 s.d. from the population mean)
were also sequenced but no further mutations were identified in
these patient groups.
Where parental DNA was available, all parents were found to be
healthy heterozygous carriers. Eight different truncating mutations
were identified in total, six of which had not been previously de-
scribed. Nine out of 11 affected patients were females, and likewise
the majority of published cases are also female (nine female, two
male, three unspecified). However, the reason for such potential
skewing in sex ratio is not readily evident.
c.2440C>T (p.Arg814∗) was identified recurrently, present in 10
of the 11 cases. High density genotyping of SNPs surrounding LIG4
in 10 families harboring c.2440C>T identified a common haplo-
type of at least 2 Mb in the two families, F4 and F8, establishing
that c.2440C>T represented a founder mutation (Supp. Fig. S1).
Three further families, F1, F2, and F6, also shared 6–12 SNPs of
the same haplotype located adjacent to the gene suggesting the mu-
tation could share the same ancestral origin in these patients too.
Importantly, the mutation was also observed in other haplotypes in
three of the patients (F3, F5, F9), establishing that c.2440C>T is a
disease-causingmutation, independent, and distinct from other co-
segregating variants. c.2440C>T coincides with aCpG site and could
therefore represent a mutational hotspot. c.1271 1275delAAAGA
(p. Lys424Argfs∗20) was present in six families however
no common haplotype associated with this mutation was
observed.
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Figure 1. Growth is significantly more impaired both at birth and postnatally in 11 cases with LIG4 mutations in comparison with previously
described patients. Measurements plotted as Z-scores (standard deviation of measurement from population mean for age and sex) for previously
reported cases (gray) alongside the patients reported here (black) for each growth parameter. A: Measurements at birth. B: Most recent postnatal
measurements. Box indicates 95% confidence interval with horizontal bars at mean. Range indicated by vertical bars. Average measurements in
previously reported cases where morphometric data were provided [Ben-Omran et al., 2005; Buck et al., 2006b; Gruhn et al., 2007; Grunebaum et al.,
2008; Toita et al., 2007; van der Burg et al., 2006; Yue et al., 2013] were: mean birth weight −1.4 ± 0.8 s.d. (n = 7), birth OFC −1.9 ± 1 s.d. (n = 5) and
birth length −1.5 ± 0.7 s.d. (n = 4), postnatal height −2.4 ± 1.5 s.d. (n = 5); weight −2.4 ± 2.3 s.d. (n = 5); and OFC −5.6 ± 2.8 s.d. (n = 6). Abbreviations:
OFC, occiptofrontal circumference; Wgt, weight; Lgt, length; Hgt, height; ns, not significant. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
Truncating LIG4 Mutations Cause Severe Pre- and
Postnatal Growth Failure
Intrauterine growth retardation (IUGR) was present in all cases;
mean birthweight –3.0± 0.93 s.d. (n = 11), birthOFC –3.6± 1.37 s.d.
(n = 8), and length –3.8 ± 1.88 s.d. (n = 3) (Fig. 1). Postnatal weight,
OFC, and length were also significantly reduced in all cases; weight
–6.8 ± 1.96 s.d., OFC –10.1 ± 0.95 s.d., and length –5.1 ± 1.62 s.d.
Therefore, disproportionate microcephaly was present, with post-
natal head circumference substantially more reduced than height
(P = 0.0001). Growth failure in the current series of patients re-
sulted in extreme postnatal short stature andmicrocephaly that was
significantly greater than previously reported cases (Fig. 1).
Facial Features, Malformations, and Cognition in LIG4
Mutation Positive Patients
All patients had a similar facial appearance (Fig. 2). Common fea-
tures in early childhood included fine sparse hair, epicanthic folds,
wide depressed nasal bridge, broad nasal tip, and a prominent chin.
No hypodontia was reported (a characteristic feature of patients
with mutations in PCNT (MOPDII) [Rauch et al., 2008]). A num-
ber of malformations were present (Table 2), although these were
individually at low frequency, as observed in NBS [Weemaes, 2000].
Congenital hip dysplasia was the only commonly reported abnor-
mality, occurring in three individuals (F3, F5, F6). Severe vomiting
episodes were also reported in one case (F6), the cause of which has
not yet been determined. These episodes have occurred from birth
and resulted in significant feedingdifficulties throughout childhood.
Primary ovarian failure was also reported in both female patients
who have so far reached pubertal age.
Development was reported to be normal in three cases, mildly
delayed in six and moderately delayed in one (Table 2). In those
in which developmental delay had been reported, impairment in
expressive language skillswaspredominant.All school-agedchildren
were in mainstream school with additional support being provided
where required. One patient died at the age of 6 months following
severe infections from birth and therefore developmental data is not
available (F10).
Marked Thrombocytopenia with Milder Leukopenia Occurs
Frequently in Early to Mid-Childhood
Nine patients (>80%) have had documented cytopenia requiring
platelet transfusions with no apparent trigger (Table 2). In seven
of these patients, the first episode occurred after recruitment to
the study (Table 3), with the earliest episode at 2 years of age (F3
and F4) and the latest at 15 years (F1.1). In all the cases, platelets
were the most significantly affected cell type (calculated as per-
cent of normal; 11.8% ± 8 s.d., P = 0.0001) followed by leukocytes
(33.7% ± 19 s.d., P = 0.0001). Hemoglobin levels were only mildly
reduced (79.3% ± 13 s.d., P = 0.002) (Fig. 3A). Bone marrow aspi-
ration performed in four individuals demonstrated a hypocellular
marrow without morphological abnormalities. In eight patients, a
progressive course of bonemarrow failure was evident with increas-
ing transfusion frequencywith age (Fig. 3B).However, Patient F1.1 is
currently no longer transfusion dependent although indices remain
subnormal on recent investigation (Table 3). Lympho-reticular ma-
lignancy has not been observed in any of the 11 cases with the oldest
patient being 21years at time of publication.
Impaired Adaptive Immunity is Apparent on Immunological
Investigation
At recruitment to the study, immunodeficiency was not clinically
suspected in 10 of the 11 cases. Retrospectively, several children
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Figure 2. Facial features of six LIG4 cases with microcephalic primordial dwarfism. Age of patient at time of photos; F1.1 20 years, F1.2 14 years,
F2 (a) 3 years and (b) 6 years 10 months, F3 (a) 3 months and (b) 10 months, F5 20 months, F6 4 years, F8 6 years, F9 6yrs 2 months, and F10 5 months.
Table 2. Anthropometric Data and Clinical Findings
A. Anthropometric Data B. Clinical Data
Pt Sex Gestn /weeks
BW/s.d.
(kg)
Birth OFC /s.d.
(cm)
Age at
examination
OFC/s.d.
(cm)
Height/s.d.
(cm)
Developmental
Delay Malformations and additional features
F1.1 F 38 – 3.6 – 4.87 17y6m – 9.4 – 6 Mild Small cerebral aneurysm, primary ovarian
failure(1.59) (27.75) (42.5) (127)
F1.2 F 40 – 2.2 N/A 11y9m – 9.9 – 4.3 Mild–moderate Atrial–ventricular septal defect, atrophic
kidney, rib hypoplasia, fusion of carpal
bones, copper beaten skull, platybasia,
abnormal C1 vertebrae and primary
ovarian failure
(1.96) (41.5) (117.5)
F2 F 33 – 3.3 – 4.07 7y10m – 12.3 – 5 Mild Anal atresia with rectovaginal fistula,
esotropia(1.01) (25) (37.9) (99)
F3 F 37 – 3.3 – 4.17 2y2m – 10.8 – 6.3 Mild Unilateral congenital hip dysplasia, cutis
marmorata(1.58) (28) (36.3) (68.5)
F4 F 40 – 3.8 N/A 2y6m – 8.9 – 3.6 None Psoriasis
(1.84) (39) (78.4)
F5 M 38 – 1.6 – 2.72 2y – 9.1 – 5.3 None Unilateral congenital hip dysplasia
(2.44) (30.5) (38.2) (70.4)
F6 F 32 – 2.95 – 1.94 2y – 10.21 – 3.08 Mild Congenital hip dysplasia, 2/3 toe
syndactyly, excessive vomiting
(gastrostomy in situ)
(0.95) (27) (36.5) (75)
F7 F 37 – 4.1 – 4.21 3y8m – 10.03 – 5.15 None None
(1.29) (27.5) (38.8) (79)
F8 F 34 – 2.93 N/A 1y9m – 9.6 – 6.2 Mild None
(1.23) (37) (65)
F9 M 37+ – 1.4 – 1.6 5y6m – 10.8 – 2.9 Mild Hypopigmentation, hypermobile knees,
single palmar crease, 2/3 toe syndactyly,
sandal gap
(2.25) (30.8) (39) (98)
F10 M 37 – 4.0 – 5.33 3m – 10.1 – 8.4 N/A Pre-axial polydactyly 2/5 toe syndactyly,
dysplastic kidney and dysgenesis of
corpus callosum.
(1.3) (26.5) (29) (43)
Anthropometric data stated as Z scores (standard deviation from population mean for age and sex), actual measurements in brackets.
Gestn , gestation; BW, birth weight; OFC, occipitofrontal circumference; s.d., standard deviation; N/A, not available; m, month; y, year.
(F1.2, F3, F6, F9) have had recurrent common childhood illnesses
(respiratory, skin, and gastrointestinal) and one patient (F1.1) had
a severe influenza illness requiring hospitalization despite vaccina-
tion. In one patient (F10), a diagnosis of SCID became clinically
apparent at an early age with recurrent infections from birth and
death at 6 months because of an acute gastric bleed in association
with a clinical sepsis syndrome. Immune function was noted to be
profoundly impaired on investigation in this patient [Ijspeert et al.,
2013].
Subsequent to diagnosis with Ligase IV deficiency, detailed im-
munological investigations have been performed in many of the
remaining patients (Table 3), demonstrating hypogammaglobuline-
mia in seven of the eight patients tested, and in the seven patients for
which T/B cell subset data are available, B cell counts were severely
80 HUMANMUTATION, Vol. 35, No. 1, 76–85, 2014
Ta
bl
e
3.
Cl
in
ic
al
Co
ur
se
of
Pa
tie
nt
s
w
ith
Fu
rt
he
rD
et
ai
ls
of
H
em
at
ol
og
ic
al
an
d
Im
m
un
e
In
ve
st
ig
at
io
n
B
.C
u
rr
en
t
H
em
at
ol
og
ic
al
Te
st
R
es
u
lt
s
C
.C
u
rr
en
t
Im
m
u
n
ol
og
ic
al
Te
st
R
es
u
lt
s
A
.F
ea
tu
re
s
at
re
fe
rr
al
W
C
C
Im
m
u
n
og
lo
bu
lin
s
g/
dl
P
t
A
ge
of
re
fe
rr
al
to
st
ud
y
H
em
at
ol
og
y
In
cr
ea
se
in
In
fe
ct
io
n
O
ns
et
of
cy
to
pe
ni
a
A
ge
at
m
ea
su
re
-
m
en
ts
ho
w
n
H
b
g/
dl
To
ta
l
10
3
/μ
l
N
eu
t
%
Ly
m
ph
%
P
lt
s
10
3
/μ
l
A
ge
at
m
ea
su
re
-
m
en
ts
sh
ow
n
Ig
G
Ig
A
Ig
M
Ly
m
ph
oc
yt
e
su
bs
et
C
el
ls
/μ
l
A
nt
ib
od
y
re
sp
on
se
to
V
ac
ci
na
ti
on
F1
.1
17
y
6m
on
th
pe
ri
od
pa
n
cy
to
p
en
ia
–
se
lf
re
so
lv
ed
M
ild
15
y
20
y
8.
2
1.
5
53
40
30
15
y
4.
31
1.
06
0.
14
C
D
3
68
0,
C
D
8
38
0,
C
D
4
24
0,
C
D
19
0
N
/A
N
aı¨
ve
C
D
4
an
d
C
D
8
co
u
n
ts
ve
ry
lo
w
F1
.2
14
y
Pe
rs
is
ta
n
t
pa
n
cy
to
p
en
ia
M
ild
8y
14
y
10
.1
1.
1
36
64
14
14
y
5.
59
1.
29
0.
76
C
D
3
66
0,
C
D
8
37
0,
C
D
4
19
0,
C
D
19
10
N
/A
N
aı¨
ve
C
D
4
an
d
C
D
8
co
u
n
ts
ve
ry
lo
w
F2
3y
O
n
e
cy
to
p
en
ic
ep
is
od
e
se
lf
-r
es
ol
ve
d
N
on
e
3y
3y
12
.6
1.
8
55
24
43
In
pr
og
re
ss
N
/A
N
/A
N
/A
N
/A
N
/A
F3
4m
N
on
e
M
ild
2y
2y
11
.1
2
30
40
18
2y
3.
7
0.
58
0.
74
C
D
3
71
0,
C
D
8
17
0,
C
D
4
50
0,
C
D
19
ve
ry
lo
w
Po
or
re
sp
on
se
to
pn
eu
m
oc
oc
ca
l
va
cc
in
e
F4
2y
N
on
e
N
on
e
2y
6y
8.
2
2.
34
N
/A
N
/A
32
6y
Lo
w
N
/A
N
/A
C
D
4
lo
w
an
d
C
D
19
ve
ry
lo
w
Po
or
re
sp
on
se
to
pn
eu
m
oc
oc
ca
l
va
cc
in
e
F5
1y
N
on
e
N
on
e
N
ot
ap
pa
re
n
t
at
3y
N
/A
N
/A
N
/A
N
/A
N
/A
N
/A
2y
3.
66
0.
8
0.
62
C
D
3
46
7,
C
D
8
20
4,
C
D
4
16
4,
C
D
19
6
To
ta
ll
ym
p
h
co
u
n
t
re
d
u
ce
d
N
/A
F6
N
eo
n
at
e
N
on
e
M
ild
3y
10
m
3y
10
m
8.
5
4.
9
55
32
42
4y
5.
76
4.
23
0.
27
C
D
3
98
3,
C
D
8
29
2,
C
D
4
58
3,
C
D
19
11
Te
ta
n
u
s
an
d
di
ph
th
er
ia
n
or
m
al
,H
iB
an
d
pn
eu
m
oc
oc
ci
lo
w
F7
3y
8m
N
on
e
N
on
e
3y
9m
4y
4m
11
.9
4.
9
54
.3
26
3
In
pr
og
re
ss
N
/A
N
/A
N
/A
N
/A
N
/A
F8
4y
N
on
e
N
on
e
6y
6y
2m
8.
2
3
N
/A
N
/A
33
6y
4.
8
2.
4
<
0.
3
N
/A
N
/A
F9
2y
6m
N
on
e
M
ild
6y
6y
11
.7
5.
6
60
.8
27
.2
78
.1
5y
6m
9.
7
3.
1
1.
0
C
D
3,
C
D
8
&
C
D
4
n
or
m
al
,C
D
19
ve
ry
lo
w
N
/A
In
cr
ea
se
in
in
fe
ct
io
n
s:
“M
ild
”
de
fi
n
ed
as
an
in
cr
ea
se
d
fr
eq
u
en
cy
of
co
m
m
on
pa
th
og
en
s
(u
pp
er
an
d
lo
w
er
re
sp
ir
at
or
y,
sk
in
,
an
d
ga
st
ro
in
te
st
in
al
)
or
in
cr
ea
se
d
se
ve
ri
ty
of
a
si
n
gl
e
ill
n
es
s
ab
ov
e
th
at
de
em
ed
n
or
m
al
fo
r
ch
ild
h
oo
d
by
th
ei
r
cl
in
ic
ia
n
.
A
bs
ol
u
te
fu
ll
bl
oo
d
co
u
n
t
va
lu
es
ar
e
th
e
m
os
t
re
ce
n
t
re
co
rd
ed
in
w
h
ic
h
cy
to
p
en
ia
is
de
m
on
st
ra
te
d.
N
or
m
al
ra
n
ge
of
ab
so
lu
te
co
u
n
ts
va
ri
es
w
it
h
ag
e,
se
x,
an
d
la
bo
ra
to
ry
m
et
h
od
s
bu
t
ap
pr
ox
im
at
e
re
fe
re
n
ce
ra
n
ge
s
ar
e
as
fo
llo
w
s:
H
b
10
.8
–1
3.
9
g/
dl
,
To
ta
lW
C
C
5.
5–
12
.9
×1
03
/μ
l,
N
eu
t3
0%
–6
0%
,L
ym
ph
20
%
–5
0%
,P
lt
s
13
0–
40
0
×1
03
/μ
l,
Ig
G
5.
65
–1
7.
65
g/
dl
,I
gA
0.
85
–3
.8
5
g/
dl
,I
gM
0.
55
–3
.7
5
g/
dl
,T
ot
al
T
ly
m
ph
oc
yt
es
(C
D
3+
)
87
0–
20
80
/μ
l,
T
h
el
p
er
su
bs
et
(C
D
4+
)
53
0–
12
90
/μ
l,
T
cy
to
to
xi
c
su
bs
et
(C
D
8+
)
22
0–
96
0/
μ
l,
B
ly
m
ph
oc
yt
es
(C
D
19
+
)
10
0–
40
0/
μ
l.
Le
ve
ls
co
n
si
de
re
d
be
lo
w
n
or
m
al
ra
n
ge
(a
cc
or
di
n
g
to
lo
ca
ll
ab
or
at
or
y)
ar
e
h
ig
h
lig
h
te
d
in
bo
ld
.R
es
u
lt
s
fo
r
pa
ti
en
t
F1
0
ar
e
de
ta
ile
d
in
Ij
sp
ee
rt
et
al
.(
20
13
).
H
b,
h
em
ag
lo
bi
n
;W
C
C
,w
h
it
e
ce
ll
co
u
n
t;
P
lt
s,
pl
at
el
et
co
u
n
t;
N
eu
t,
N
eu
tr
op
h
il
co
u
n
t;
Ly
m
ph
,l
ym
ph
oc
yt
e
co
u
n
t;
B
M
T,
bo
n
e
m
ar
ro
w
tr
an
sp
la
n
t;
N
/A
,n
ot
av
ai
la
bl
e
or
n
ot
p
er
fo
rm
ed
;m
,m
on
th
;y
,y
ea
r.
HUMANMUTATION, Vol. 35, No. 1, 76–85, 2014 81
Figure 3. Platelets are the most significantly affected cell type in cytopenic episodes in patients with LIG4 mutations and severity of episodes
increases with age. Values are shown as percentage of average normal count. A: Documented blood counts from nine patients during the most
recent cytopenic episode. B: Serial blood counts in one patient (F8) over time demonstrating increasing frequency of transfusions with age. Arrows
indicate when platelet transfusion occurred.
depleted, alongside lessmarked T cell subset deficiencies. Bonemar-
row transplantation (BMT) is now underway in patient F3, and is
being considered in several others (F1.2, F6, and F7).
Repair of IR Induced DSB is Impaired in Patient Cells
Radiosensitivity of LIG4 lymphoblastoid cells was examined us-
ing a colony survival assay previously established for the testing
of A-T patients [Sun et al., 2002]. Increased sensitivity to DNA
damage was seen in all three patients tested (F2, F5, and F7), with
reduced survival of cells (3%–5% cell survival) following exposure
to 1 Gray of ionizing radiation (lab reference range for wild-type
cells: 50.1% ± 13.5, n = 24). This is similar to the sensitivity seen in
ataxic telangectasia patient cells (13.1% ± 7.2, n = 104) and that ob-
served in previous studies of LIG4 patients [O’Driscoll et al., 2001].
Increased cellular sensitivity to ionizing radiation is also present in
patient F10 [Ijspeert et al., 2013].
Phenotype Severity Correlates with the Position of the
Truncating Mutation
The coding sequence for LIG4 is solely in the terminal exon
(Fig. 4) and therefore transcripts should not be targeted for non-
sense mediated decay. All mutations identified in our cohort were
predicted to truncate the LIG4 protein to varying degrees, and posi-
tion of truncatingmutations correlated with the phenotype severity
observed (Fig. 4).
Discussion
The Phenotype Spectrum of Patients with LIG4 Mutations
Here, we report the identification of LIG4 mutations in 11 pa-
tients with profound global growth failure, expanding the pheno-
typic spectrum associated with dysfunction of the ligase IV enzyme.
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Figure 4. Degree of protein truncation correlates with severity of growth failure and immuno deficiency. A: Schematic of the LIG4 gene, which
contains two exons, with exon 2 encoding the 911aa protein. B: LIG4 protein domain structure: The protein is composed of an enzymatic domain
in which highly conserved sequence motifs have been identified (dark gray) [Marchetti et al., 2006; Shuman and Schwer, 1995], and a C-terminal
XRCC4 binding domain composed of 2 BRCT domains (light gray) with a linker region that contains the minimal XRCC4 binding motif (black) [Sibanda
et al., 2001]. C and D: Position of truncating mutations correlating with phenotype. D: Biallelic mutations representative for each group are depicted:
(i) Late truncating; a homozygous c.2440C>T, p.Arg814∗ mutation, represents the mildest truncating mutation reported, only affecting the latter part
of the XRCC4 binding domain and is associated with normal development and a mild growth phenotype [Ben-Omran et al., 2005]. (ii) Late and mid
truncating; the majority of cases described in this manuscript (F1.1-F9) carry the c.2440C>T mutation combined with a more proximally truncating
mutation associated with a severe growth phenotype, chronic or progressive cytopenia and immune dysfunction. (iii) Mid and early truncating
mutations; the most severely affected case with SCID (F10) carried a “mid-truncating” mutation which completely removed the XRCC4 binding
site in combination with an “early” truncating mutation that removed the entire enzymatic domain. Abbreviations: ORF, open reading frame; UTR,
untranslated region.
Previously, mutations have been associated with clinical presenta-
tions ranging from lympho-reticular malignancy in childhood, to
severe immunodeficiency (SCID) with mortality in the first few
months of life [Ben-Omran et al., 2005; Buck et al., 2006b; En-
ders et al., 2006; Grunebaum et al., 2008; O’Driscoll et al., 2001;
O’Driscoll et al., 2004; Riballo et al., 1999; Riballo et al., 2001; Toita
et al., 2007; Unal et al., 2009; van der Burg et al., 2006]. Micro-
cephaly is common to both previously reported and current cases
occurring in more than 80% of all reported patients to date. Al-
though reduced stature has been noted in some cases [Buck et al.,
2006b; Gruhn et al., 2007; Grunebaum et al., 2008; O’Driscoll et al.,
2001; Toita et al., 2007; Unal et al., 2009; Yue et al., 2013], such
severe global growth failure has not been previously documented.
Given the substantial number of additional LIG4 patients identified
by our study, the “MPD” phenotype represents a previously under
recognized group of LIG4 patients. However, this phenotype might
well have been anticipated given the ∼40% reduction in body size
reported in two LIG4 hypomorphic mouse models [Nijnik et al.,
2007; Rucci et al., 2010].
The marked growth phenotype in our cohort might suggest that
these cases could be molecularly distinct from previous reports.
In contrast to previous cases with primarily missense mutations,
all of our patients had compound heterozygous truncating LIG4
mutations. As all these truncating mutations are in the terminal
exon (and therefore would not be expected to be susceptible to
nonsense mediated decay), transcripts encoding truncated proteins
are predicted to be expressed at normal levels. Notably, disease
severity correlated with position of mutation (Fig. 4), with two
“early” truncatingmutations having themost severe phenotypewith
SCID,while the combination of an “early” truncatingmutationwith
the c.2440C>T (p.Arg814∗)mutation led to global growth reduction
without clinically apparent immunodeficiency before investigation.
Three cases with a similar combination of truncating mutations
have been reported previously. Anthropometric data are unavailable
for two of these patients [O’Driscoll et al., 2001], however, a third
recently identified patient has a similar clinical picture to our patient
group [Yue et al., 2013]. Additionally, a previously reported patient,
with c.2440C>T /c.2440C>T mutations had a milder phenotype,
with microcephaly but normal stature [Ben-Omran et al., 2005]
and without clinical suspicion of immunodeficiency or cytopenia.
Therefore, the degree of protein truncation appears to correlate with
phenotype severity.
Previous biochemical and cellular studies may explain this cor-
relation, as the c.2440C>T mutation impairs enzymatic function
less than earlier truncating mutations [Girard et al., 2004]. Codon
Arg814 lies at the start of the second BRCT domain of the XRCC4
binding site [Critchlow et al., 1997]. Loss of this BRCT domain
impairs XRCC4 binding [Girard et al., 2004], although the major
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determinant of XRCC4 binding, the “intervening linker sequence,”
is retained [Grawunder et al., 1998b]. As XRCC4 binding is required
for LIG4 stability [Bryans et al., 1999], the p.Arg814∗ mutation re-
sults in impaired LIG4 cellular activity, with reduced LIG4 protein
levels [O’Driscoll et al., 2001] and also impairs ligase activity [Girard
et al., 2004]. Earlier (close to the N-terminus) protein truncation
leads to a more complete loss of function, with truncated protein
resulting from the c.2094C>G (p.Arg580∗)mutation not interacting
with XRCC4 or localizing to the nucleus [Girard et al., 2004].
Clinical Implications: Diagnosis and Management
The availability of clinical data from a series of 11 patients permits
a more comprehensive description of common facial, developmen-
tal, and hematological features for Ligase IV syndrome, which could
be diagnostically useful. A facial gestalt is apparent across the pa-
tient group, with fine sparse hair, epicanthic folds, wide depressed
nasal bridge, broad nasal tip, and prominent chin in early childhood
(Fig. 2), in keeping with the facial features of a previously reported
case [Gruhn et al., 2007]. Notably these features are somewhat rem-
iniscent of those described in Dubowitz syndrome, in which severe
microcephaly and IUGR also occurs [Tsukahara and Opitz, 1996]
and had been previously considered as a differential in some of our
patients. Furthermore, a patient initially diagnosed with Dubowitz
syndrome has recently been reported with biallelic truncating mu-
tations in LIG4 [Yue et al., 2013].
Bone marrow failure appears to be a strongly discriminative di-
agnostic feature of Ligase IV syndrome, occurring in ∼70% of all
reported cases to date. However, cytopenia may not be evident at
initial presentation, particularly in very young children. LIG4 mu-
tations should also be considered in the differential diagnosis of
Fanconi anemia syndrome, especially in patients withmicrocephaly
and growth failure but without limb reduction defects. In contrast
to many previous reports [Buck et al., 2006b; Enders et al., 2006;
Grunebaum et al., 2008; van der Burg et al., 2006], immunodefi-
ciency was not suspected clinically beforemolecular diagnosis in the
majority of patients but further investigation has revealed signifi-
cant humoral and cellular immunodeficiency. This highlights the
need for early recognition of Ligase IV deficiency and subsequent
immunological investigation even in asymptomatic patients.
Predisposition to malignancies is common in disorders with de-
fective double-strand DNA break damage repair such as ataxia-
telangiectasia and NBS [Nahas and Gatti, 2009]. Although no cases
of malignancy have occurred in our case series, malignancies have
been described in 25% of LIG4 cases overall. Although predomi-
nantly lympho-reticular [Ben-Omran et al., 2005; Buck et al., 2006b;
Enders et al., 2006; Riballo et al., 1999; Toita et al., 2007], a case of
anal carcinoma at the age of 34 years has recently been reported [Yue
et al., 2013].Asourpatients’ cells exhibit sensitivity to ionizing radia-
tion comparable to that reported previously [O’Driscoll et al., 2001],
an increased malignancy risk should be anticipated [Nahas and
Gatti, 2009]. Avoidance of nonessential exposure to ionizing radia-
tion is clearly desirable in LIG4 patients. Likewise, if BMT becomes
necessary, modification of conditioning regimes appears to be im-
portant. Additionally, increased sensitivity to the immunosuppres-
sant, Cyclosporin A has also been suggested [O’Driscoll and Jeggo,
2008] and successful transplantation has nowbeen reported [Enders
et al., 2006; Gruhn et al., 2007; Grunebaum et al., 2008; Unal et al.,
2009].
Given the hypersensitivity to radiation, Ligase IV syndrome is
an important diagnosis to make [Nahas and Gatti, 2009]. It is a
relatively frequent cause of MPD, a phenotype group with high ge-
netic heterogeneity. Only mutations in PCNT (20%) and RNU4atac
(2.4%) are seen as frequently in our experience (unpublished data,
LSB, JEM, APJ). c.2440C>T (p.Arg814∗) has been previously iden-
tified in European populations, with an allele frequency of 0.001
and 0.003, in Exome Variant Server and “1000 Genome” databases,
respectively. Therefore, there may be many unrecognized cases of
LIG4 deficiency. In particular, the frequency of c.2440C>T homozy-
gotes would be expected to be 1 in 100,000 to 1 in 1,000,000, po-
tentially presenting as nonsyndromic microcephaly with normal
development [Ben-Omran et al., 2005]. For those that reach the ge-
netics clinic, the routine adoption of high-throughput sequencing
in molecular diagnostics is likely to improve ascertainment; how-
ever, appropriate setting of allele frequency filters is crucial. This is
well illustrated by our initial oversight of the LIG4mutations when
all dbSNP annotated variants, including the c.2440C>T mutation,
were removed.
In summary, we report that mutations in LIG4 occur in patients
presenting with extreme growth failure, extending the phenotypic
spectrum of Ligase IV deficiency. We establish that a recurrent
mutation present in conjunction with a more severely truncating
mutation confers profound growth impairment with progressive
bone marrow failure and immunodeficiency evident on laboratory
investigation.
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